TORONTO, Nov. 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it is participating in a GBM (glioblastoma multiforme) Awareness Day as a co-host with Voices Against Brain Cancer.
The event will take place on Wednesday, November 12, 2008, at the Four
Seasons Hotel in New York City. The panel discussion will begin at 4:15pm
ET. Dr. Alan M. Ezrin, President and Chief Executive Officer of Bradmer
will present the Company's Neuradiab(TM) therapy, and an expert panel of
physicians will discuss current trends and therapeutic advancements in the
treatment of GBM, the most common and most advanced form of brain cancer.
The expert panelists include:
Steven Rosenfeld, M.D., Columbia University Medical Center (Moderator)
Henry Friedman, M.D., Duke University Medical Center
Keith Black, M.D., Cedars-Sinai Medical Center
Pamela New, M.D., Methodist Neurological Institute
Joycelyn Speight, M.D., Ph.D., University of California, San Francisco,
David A. Reardon, M.D., Duke University Medical Center
Michael R. Zalutsky, Ph.D., Duke University Medical Center
David M. Bailey, Patient Advocate
The event will be broadcast live via a webcast presentation accessible from the Company's website at http://www.bradmerpharma.com. Please connect at least 15 minutes prior to the start time to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived for 30 days on Bradmer's website.
About Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most common and most advanced form
of brain cancer with approximately 30,000 new cases diagnosed each year in
the world's seven largest healthcare markets. Unlike many other soli
|SOURCE Bradmer Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved